Prevention of mucositis with Calphorinz solution for patients undergoing transplantation.
Not Applicable
- Conditions
- Health Condition 1: null- Preventing mucositis in Patients undergoing stem cell transplantation
- Registration Number
- CTRI/2017/07/009007
- Lead Sponsor
- Institutional fundingChristian Medical College Vellore
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients undergoing allogenic or autologous stem cell transplantation using the following conditioning regimens â?? For Allogeneic - [Cyclophosphamide and TBI, Busulfan based, Treosulfan based, Melphalan 140 mg/m2]; For autologous â?? [Melphalan 140 -200 mg/m2, BEAM conditioning]
Exclusion Criteria
Patients undergoing reduced intensity conditioning Patients unwilling to sign consent
Children < 5 years of age
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study if the use of Calphorinz suspension will reduce the incidence of severe mucositis [Grade III & IV ]from 70% to 40% in patients undergoing allogeneic or autologous stem cell transplantation.Timepoint: Till Day 21
- Secondary Outcome Measures
Name Time Method To study if the use of Calphorinz suspension will reduce the incidence of severe mucositis [Grade III & IV ]from 70% to 40% in patients undergoing allogeneic or autologous stem cell transplantation.Timepoint: Till Day 14